Subscribe
kuzma-shutterstock-com-1
Kuzma / Shutterstock.com
11 December 2015Americas

PTAB rejects Vimovo IPR trial

The Patent Trial and Appeal Board (PTAB) has rejected the Coalition for Affordable Drugs' attempt to invalidate a patent covering Pozen’s Vimovo (naproxen and esomeprazole magnesium) drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Bass returns funds but vows to continue pharma fight
24 February 2016   Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Bass returns funds but vows to continue pharma fight
24 February 2016   Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another.

More on this story

Americas
Bass returns funds but vows to continue pharma fight
24 February 2016   Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York